Interesting PRCT Put And Call Options For February 2026

PROCEPT BioRobotics (PRCT) at $33.92 offers income-oriented option plays: a $30 put (bid $1.95) nets an effective purchase basis of $28.05 (≈12% below current price) with a 67% probability of expiring worthless and a 6.50% cash-return (39.54% annualized) YieldBoost. Alternatively, selling a $37.50 covered call (bid $1.30) on owned shares would cap upside at $37.50 but produce a 14.39% total return if called by Feb 2026, with a 64% chance the call expires worthless and a 3.83% premium boost (23.31% annualized). Implied volatilities are 64% (put) and 69% (call) versus a trailing 12-month volatility of 54%.

Analysis

Market structure: The immediate winners are option premium sellers (retail/income managers) who can pocket 6.5% cash-secured yield-to-expiry by selling the $30 Feb‑2026 put; losers are levered long speculators who get squeezed by assignment or by IV re‑pricing. Elevated IV (64–69%) vs realized vol (54%) signals demand for downside/uncertainty protection in small‑cap medtech and a willingness to pay for time — liquidity will concentrate in listed strikes around $30–$37.50, with limited cross‑asset spillover beyond higher idiosyncratic correlations with medtech ETF IHI and short‑term volatility proxies (VIX delta exposures minimal).

Risk assessment: Tail risks are binary clinical/regulatory events (FDA rejection, adverse device safety signal) that can wipe out 30–70% of market cap within days; cash‑secured put sellers face assignment shock. Time horizon: days — theta decay benefits sellers; 1–6 months — IV mean reversion or a catalyst re‑prices options; 6–24 months — commercialization/margin outcomes matter. Hidden dependencies include float, insider lockups, upcoming data/earnings dates and institutional block trades that can flip supply/demand quickly.

Trade implications: Direct: small, cash‑secured put sell on PRCT: sell 1x $30 Feb‑2026 put @ $1.95 (max 0.5–1.0% portfolio), or convert to a put‑spread (sell $30 / buy $25) to cap tail risk. Covered‑call for existing holders: sell $37.50 Feb‑2026 @ $1.30 to harvest ~14% gross to target; avoid long calls — IV premium is elevated. Relative: long PRCT vs short IHI (dollar‑neutral 1:1) to express idiosyncratic upside while hedging sector beta.

Contrarian angles: Consensus underprices binary regulatory risk but overprices continuous volatility — implied > realized suggests premium sellers are marginally favored long term. If PRCT posts neutral/positive clinical updates, IV collapse could generate 20–40% upside in stock and crush option sellers; conversely an adverse binary drives >50% downside. Historical parallel: small medtechs after mixed trial readouts often see 30–50% swings; position sizing and defined‑risk structures matter most.

Key Decisions for Investors

• Establish a cash‑secured short position: sell-to-open PRCT Feb‑2026 $30 put at $1.95 (or better) representing ≤1.0% portfolio risk; if assigned, cost basis = $28.05. Close position if PRCT falls below $24.50 (≈‑28%) or if premium widens by >50%.
• For existing PRCT holders, sell-to-open Feb‑2026 $37.50 covered calls at $1.30 to lock ~14% upside through expiry; roll or buy back if PRCT >$40 or IV spikes >80%.
• If worried about binary tail risk, convert the sell‑put into a defined‑risk spread: sell $30 / buy $25 Feb‑2026 put spread sizing ≤0.5% portfolio to cap max loss to known width. Do not buy naked long calls given IV premium >60%.
• Relative trade: construct dollar‑neutral pair long PRCT / short IHI (1:1 dollar) with a small position (0.5–1% net) to capture idiosyncratic recovery while hedging sector moves; trim if PRCT outperforms IHI by +25% in 90 days.
• Monitor: track IV vs realized gap (threshold: IV>realized+10%) and any FDA/clinical notices over next 90 days; act within 48–72 hours of a press release to re‑size or hedge positions.